Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Tibolone and endometrial cancer: a cohort and nested case-control study in the UK.

de Vries CS, Bromley SE, Thomas H, Farmer RD.

Drug Saf. 2005;28(3):241-9.

PMID:
15733028
2.

Endometrial cancer and hormone-replacement therapy in the Million Women Study.

Beral V, Bull D, Reeves G; Million Women Study Collaborators..

Lancet. 2005 Apr 30-May 6;365(9470):1543-51.

PMID:
15866308
3.

Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997.

Pukkala E, Tulenheimo-Silfvast A, Leminen A.

Cancer Causes Control. 2001 Feb;12(2):111-5.

PMID:
11246839
4.

Tibolone: cancers of the breast and endometrium.

[No authors listed]

Prescrire Int. 2006 Jun;15(83):107.

PMID:
16764100
5.

Endometrial cancer patients and tibolone: a matched case-control study.

Lee KB, Lee JM, Lee JK, Cho CH.

Maturitas. 2006 Oct 20;55(3):264-9.

PMID:
16678984
6.

Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study.

Wierik EJ, Hendricks PT, Boerstoel-Streefland M.

Climacteric. 2004 Jun;7(2):197-209.

PMID:
15497909
7.

Short and long term effects of tibolone in postmenopausal women.

Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, Basevi V, Marata AM, Magrini N, Maestri E.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008536. doi: 10.1002/14651858.CD008536.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Oct 12;10 :CD008536.

PMID:
22336846
8.

Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.

Renoux C, Dell'aniello S, Garbe E, Suissa S.

BMJ. 2010 Jun 3;340:c2519. doi: 10.1136/bmj.c2519.

9.

Myocardial infarction risk and hormone replacement: differences between products.

de Vries CS, Bromley SE, Farmer RD.

Maturitas. 2006 Feb 20;53(3):343-50.

PMID:
16040209
10.

[Modern tendencies in HRT of patients treated for endometrial cancer].

Ivanov C.

Akush Ginekol (Sofiia). 2009;48(2):20-2. Bulgarian.

PMID:
20198772
11.

Hormone replacement therapy use and variations in the risk of breast cancer.

Opatrny L, Dell'Aniello S, Assouline S, Suissa S.

BJOG. 2008 Jan;115(2):169-75; discussion 175.

12.

Hormone replacement therapy use and the risk of stroke.

Renoux C, Dell'aniello S, Garbe E, Suissa S.

Maturitas. 2008 Dec 20;61(4):305-9. doi: 10.1016/j.maturitas.2008.09.020.

PMID:
18996656
13.

Endometrial effects of tibolone.

Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, den Hollander W, Stathopoulos V, Helmond FA.

J Clin Endocrinol Metab. 2007 Mar;92(3):911-8.

PMID:
17192288
15.

Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women.

Velthuis-Te Wierik EJ, Hendricks PT, Martinez C.

Menopause. 2007 May-Jun;14(3 Pt 1):518-27.

PMID:
17224856
16.

Attitudes and practices of Korean gynecologists towards hormone replacement therapy in endometrial cancer survivors.

Lee SJ, Yeo SG, Kang SB, Park DC.

Eur J Gynaecol Oncol. 2013;34(6):513-7.

PMID:
24601041
17.

Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case-control study.

Brøns N, Baandrup L, Dehlendorff C, Kjaer SK.

Cancer Causes Control. 2015 Jul;26(7):973-81. doi: 10.1007/s10552-015-0578-4.

PMID:
25895439
18.

The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study.

Mørch LS, Kjaer SK, Keiding N, Løkkegaard E, Lidegaard Ø.

Int J Cancer. 2016 Mar 15;138(6):1506-15. doi: 10.1002/ijc.29878.

PMID:
26421912
19.

Population-based study of risk of venous thromboembolism associated with various oral contraceptives.

Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.

Lancet. 1997 Jan 11;349(9045):83-8.

PMID:
8996419
20.

A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.

Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC.

Maturitas. 2006 Mar 20;53(4):413-23.

PMID:
16140483
Items per page

Supplemental Content

Support Center